The ultrasound surgery system developer is targeting $150m at a $1.3bn post-money valuation, with Koch Disruptive Technologies supplying $100m.
Industrial and chemicals conglomerate Koch Industries has agreed to invest $100m in InSightec, an Israel-based developer of an ultrasound surgery system for Parkinson’s disease, as part of a $150m series F round.
The corporate has committed the capital through its Koch Disruptive Technologies (KDT) subsidiary pending shareholder approval. The series F round will be sized at up to $150m and will value InSightec at $1.3bn post-money.
InSightec has created an incisionless brain surgery device called Exablate Neuro that relies on…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
